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Abstract
Background: Managing patients with polypharmacy is a challenging issue in primary care. The aim of this study is
to determine whether a patient-centered systematic review leads to more appropriate medication use in patients
without negatively affecting quality of life and the course of the disease.
Methods/Design : The trial is a two-armed, double blinded cluster-randomized controlled trial. Primary care
physicians (PCPs) will be randomly assigned to the intervention or control group. Physicians in the intervention
group undergo training with instruction of the algorithm. The control group is given a lecture on multimorbidity
and instructions for collecting data in a usual care manner.
PCPs will approach patients aged 60 years or older who are taking 5 or more drugs. The study period is 1 year.
The primary outcome measure is the change in the number of drugs 12 months after the algorithm was applied
by the PCP during consultation with the patient. Secondary outcomes are: change in the number of drugs
immediately after the encounter and 6 months later, reason for a change of the medication, discrepancy in the
decision to change between PCP and patient, number of drugs for which the patient is suggesting a change,
number of drugs the patient is taking that are not known to the PCP, time consumption of the intervention,
disease-specific variables to evaluate the course of the disease(s) for which the patient is being treated , quality of
life, barriers against using the algorithm, numbers of drugs readopted due to an unfavorable course of the disease,
and numbers of drugs which have been started.
Discussion: Answering the four questions of the algorithm requires a weighing-up of risks and benefits and
contains a shared-decision-making approach: a prioritization of the treatment goals is necessary. This can only be
done in collaboration with the patient. The majority of patients with multimorbidity are treated in the primary care
setting. This underlines the significance of our study carried out in this setting: given the high prevalence of
adverse drug events in patients with multimorbidity an intervention like ours has a large potential to reduce
drug-related morbidity.
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Background
The intake of multiple drugs (polypharmacy), overuse
and misuse of drugs are increasing problems in the care
of people with a number of health conditions (multi-
morbid) as well as older people [1, 2]. One of the prob-
lems in polypharmacy is the danger of adverse drug
reactions [3]. This leads to an increase in morbidity,
hospital admissions [4, 5], health-related costs [6] and
number of deaths [7, 8]. Paradoxically, a clear relation-
ship between polypharmacy and underuse of indicated
drugs has been shown [9–11]. Up to now, several clin-
ical tools and approaches to guide appropriate prescrib-
ing of drugs are available [11-14]. Deprescribing is a
complex process that is required for the safe and effect-
ive cessation of inappropriate medications [3]. Barriers
to and enablers of deprescribing from the point of view
of the patients as well as from primary care physicians
(PCPs) have been investigated [3, 15–18]. A recently
published study using a newly developed algorithm
for a systematic reduction of medication (Good Pallia-
tive Geriatric Practice, GPGP) showed that depre-
scribing resulted in a significant positive effect on
health in older patients [19, 20]. In our study, we
slightly adapted the GPGP algorithm and pilot-tested
the algorithm in a primary care setting to assess feasi-
bility and practicability [21]. The algorithm enforces a
systematic drug review considering patients’ perspec-
tive and preferences. As primary care physicians
(PCPs) take care of the majority of patients with mul-
timorbidity, our tool has a potentially high impact on
polypharmacy in primary care settings. Previous stud-
ies, investigating interventions to reduce polyphar-
macy, have taken place in an older persons care
setting. In primary care settings results are still lack-
ing. This study intends to bridge this gap.
Study hypothesis
The implementation of an algorithm adapted to the
GPGP leads to a reduction of polypharmacy among
patients with multimorbidity (60 years and older) in a
primary care setting.
Furthermore, this implementation does not worsen the
quality of life or the course of the disease for which the
drug was originally prescribed for (safety issues of the
intervention).
Methods/Design
We will conduct a cluster-randomized controlled trial
(randomization on PCP-practice level) with primary care
physicians in the northern part of Switzerland (see
Fig. 1). The design and methodology of our study is
based on the experiences of a small pilot study.
Pilot study
The pilot study [21] was conducted with 14 primary care
physicians. An evaluation was conducted to test the lo-
gistics, baseline measurements and the feasibility of the
study. The pilot study resulted in minor changes in the
questionnaire and an important element of shared-
decision-making was added: beside the four major
clinical problems defined by the PCP the four most
important complaints in a patient’s perspective were
added. In order to detect potential undertreatment a
special section was added entitled “medication started”.
Recruitment and eligibility of primary care physicians
PCPs are eligible for participation if they provide care in
the routine primary setting to unselected patients. About
1700 PCPs in the Canton of Zurich will be invited by a
formal letter of the Institute of Primary Care of the
University of Zurich.
PCPs who finally agree to participate will be listed in al-
phabetical order. If two PCPs of the same practice agree to
participate, the first name in the alphabet receives a num-
ber which is valid also for the second one in order to avoid
contamination between groups. Randomization will be
stratified according to the practice size (e.g. single-handed
versus group practice). The randomization scheme will be
generated by using the website Randomization.com
(http://www.randomization.com) and group assignment
will be performed by a study nurse not involved in further
data analysis. The PCPs with the corresponding numbers
will be randomly allocated to the intervention and control
group, respectively.
PCPs will be informed only after completion of the
study about the group they have been randomized to
(intervention or control group) in a debriefing session.
At this time, an education session on how to use the
algorithm will be offered to the control group.
If the number of the required 33 (see power calcula-
tion below) participating PCPs cannot be reached, the
randomization will be done with the interested PCPs
and the recruiting will be expanded to other Cantons of
the northern area of Switzerland, followed by another
randomization process.
Each PCP in the intervention and control groups will
receive a financial allowance.
Patient recruitment
All PCPs are asked to approach, consecutively and re-
gardless of the reason for the current consultation,
patients aged 60 or older who are taking 5 or more
long-term drugs.
Patient inclusion criteria
Be aged at least 60 years.
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Be taking 5 or more long-term drugs (6 months or
longer).
Patient exclusion criteria
Life expectancy less than 12 months.
Intervention
Blinding of PCPs is not possible in this study design and
even participation in a study addressing a certain topic
can influence a physician’s behavior. To achieve a degree
of blinding, PCPs are not provided with specific infor-
mation at invitation. They will receive a lecture (length:
2 hours) about multimorbidity in general and instruc-
tions for collecting data in a usual care group. PCPs
from the control group will be told that the study pur-
pose is to investigate best practices for physician-patient
communication.
PCPs in the intervention group will undergo a phy-
sicians’ training with instruction on how to use the
algorithm including a communication skills training.
The adapted GPGP-algorithm used in our trial con-
sists of four steps and is a patient-centered process.
First, the drugs are listed together with the four main
diagnoses as well as the four main disorders from the
patient’s perspective. Then the following steps will be
systematically followed (see Fig. 2):
1. Indication of the drug in this patient (identifying
undertreatment or overtreatment)
2. Do the known possible adverse reactions of the drug
outweigh the possible benefits? (Potential adverse
events)
3. Can the dosing rate be reduced with no significant
risk? (Dosing problems)
Fig. 1 Study flow chart
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4. Is there another drug that may be superior to the
one in question?
Finally, the result of this analysis will be discussed to-
gether with the patient. For each drug the PCP will note
whether the patient agrees with the recommendation.
After obtaining informed consent from the patient, a
practice nurse or the PCP creates a list of the patient’s
present medication. Then, the PCP defines the four
major clinical problems and, together with the patient,
the four most important complaints from the patients’
perspective. Physicians in the intervention group then
decide, for every drug listed, whether the indication is
correct, whether there are side effects, whether an alter-
native treatment would be suitable or whether a change
in the dosage is indicated (key questions of the algo-
rithm). After discussion with the patient, the PCP and
patient decide together whether to stop a drug, to
change the dosage of a drug or to switch to an alterna-
tive drug, with the option to restart if symptoms should
increase or the disease deteriorate.
Primary outcomes measures
Change in the number of drugs (deprescribing rate)
12 months after applying the tool.
The primary outcome will be calculated on the basis of
the medication list, provided by the practice nurse or the
PCP at baseline (before the intervention) and 12 months
afterwards.
Secondary outcome measures
Table 1 displays the secondary outcomes with the appro-
priate measuring method.
After the baseline assessment (including gender and
living situation) systematic follow-up measurements will
take place after 6 and 12 months.
Patient-reported outcomes
Quality of life (QoL) will be assessed using the EuroQol
(EQ-5D-3 L). This is a generic preference-based health
status measure that has been shown to be valid and reliable
in a variety of populations and patients groups [22–25].
Furthermore, patients are asked to determine their
QoL on a Likert scale from −2 to +2. They are asked
about their main complaint and they have to indicate
the intensity (no complaint to unsupportable) on a visual
analogue pain scale.
Disease-specific parameters
PCPs of both groups measure the following disease-
specific parameters at baseline, after 6 and after
12 months:
 Weight and blood pressure
 Glycated hemoglobin (HbA1c), for patients with
diabetes only
 Thyroid-stimulating hormone (TSH), for patients
with thyroid hormone substitution only
 Hemoglobin, for patients with iron substitution or
vitamin B12 substitution only
Furthermore, the PCP evaluates the course of the main
diseases (stable, improvement, aggravation).
Fig. 2 Improving drug therapy in primary care (adapted from [20] and [21])
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Safety outcomes
Adverse events have to be reported by the PCP at the
study center and the safety board. The following defin-
ition for adverse events is used:
 Complication of an existing disease (e.g. myocardial
infarction in a coronary heart disease patient)
 Acute illness newly diagnosed
 Hospitalization or death
In case of adverse events the safety board can consult
the medical history of the patient and, together with the
PCP, it decides whether there is a plausible connection
between intervention and adverse event.
The safety board is composed of a clinical ethicist, bio-
statistician and a geriatrician.
Data collection procedures
Patients will receive detailed written information on the
aim of the study. After giving their written informed
consent data will be collected by means of paper docu-
ments. For every patient a dossier with the different case
report forms will be created. The forms are encoded; the
code is stored at each primary care physicians’ practice.
If a case-tracking is needed (in case of adverse events) it
can be decoded. The transfer from paper to electronic
data will be carried out through a research associate
and controlled by a second research associate. Group-
ing of diagnoses and drugs will be organized by stan-
dardised databases.
Statistical analysis
The primary data analysis will follow the intent-to-treat
(ITT) approach. This means that all available data from
all individuals will be analyzed according to treatment
group assignment, regardless of whether or not each in-
dividual actually received the assigned treatment.
The primary outcome, change in the number of drugs
12 months after applying the deprescribing tool, will be
compared by using a t test for independent groups com-
parison. Hierarchical regression will be used to consider
the cluster-design for potential confounder. Determinants
associated with a change of the medication are investi-
gated by exploratory, multivariate regression analysis.
For secondary outcomes, parametric (t test) or non-
parametric tests (chi-square and Wilcoxon test) will be
used where appropriate.
Descriptive statistics will be used to describe the
study population. Drop-out and loss to follow-up will
be described.
Table 1 Secondary outcomes and the appropriate measuring method
Secondary outcomes Measuring method
1. Change in the number of drugs immediately after the
encounter and 6 months later
Medication list at baseline and after 6 months
2. Reason for a change, categorized in the 4 options of
the algorithm, number of drugs in each category 12
months after applying the tool
Medication list of the changed medications after the
intervention, with the reason for a change
3. Discrepancy in the decision to quit, change or
continue the drug between PCP and patient
Medication list after intervention with any suggestion
from the PCP for a change; medication list after the
intervention and after shared-decision-making
4. Number of drugs for which the patient is suggesting
a change
Medication lists at baseline, after 6 and 12 months
5. Number of drugs the patient is taking not known
to the PCP
Medication lists at baseline, after 6 and 12 months
6. Time consumption of the intervention Measurement of the time through the practice nurse
and the PCP
7. Disease-specific variables to evaluate the course
of the disease(s) for which the patient is being treated
Symptom scores and measurements of biometric
analysis (e.g. blood pressure monitoring, serum glucose)
and VAS scales (e.g. pain). Event rates (hospitalization,
death) and unexpected adverse event rates
8. Number of drugs readopted due to an unfavorable
course of the disease(s) (readoption rate)
Medication lists at baseline, after 6 and 12 months
9. Quality of life (QoL) Patient rating on a 5-point Likert scale
EQ-5D-3 L at baseline, after 6 and 12 months
10. Barriers perceived by patients and PCPs against
the approach/algorithm
Phone interview with the patients 13 months after
intervention
11. Number of drugs which have been started Medication lists at baseline, after 6 and 12 months
EQ-5D-3 L EuroQol health status measure, PCP primary care practitioner, VAS visual analogue scale
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In case of study discontinuation the collected data that
are hitherto available will be anonymized and evaluated.
The last observation carried forward (LOCF) method
will be used for dealing with the missing data for patients
who have dropped out. The drop-out rate and the causes
of drop-outs will be compared between the two groups to
investigate the possible influence of the intervention. To
estimate the last observation carried forward-effect a per-
protocol (PP) analysis will be applied.
Timeframe of the study
The recruitment of the PCP is planned over 2 months
between March and May 2015.
Patients’ eligibility screening and patient inclusion is
projected within a period of 4 months. The aim is to in-
clude 1 patient/week per PCP.
Ethics approval
The study protocol is approved by the Ethics Committee
of the Canton of Zurich (reference KEK-ZH-number
2015–0595).
Patient informed consent
Previous to study participation, patients receive written
and verbal information about the content and extent of
the planned study from the PCPs. In case of acceptance,
they sign the informed consent form.
Data security/disclosure of original documents
The patient names and all other confidential information
fall under medical confidentiality rules and are treated
according to appropriate Federal Data Security Laws.
The patient names are not accessible to the study staff.
Sample size calculation
Assuming a 0.05 2-sided significance level, 30 clusters
(on PCP-level) including 13 patients each would have an
80 % power to detect a difference of 1 drug, which we
consider to be clinically relevant.
Based on previous studies [14] we assumed an
intracluster correlation coefficient (ICC) of 0.02 for the
primary outcome and a standard deviation of 2.8 [21]. In
consideration of a drop-out rate of 10 %, 33 PCPs (16 re-
spectively 17 PCPs with 215 patients in each arm) are
needed.
Discussion
The aim of this study is to determine whether a system-
atic review with a specific algorithm leads to more ap-
propriate medication use in patients with multimorbidity
(60 years and older) without worsening their quality of
life and the course of the disease. Up to now, similar in-
terventions have been tested in older populations but
not in a primary care setting. In this setting, it is crucial,
that an intervention is time-saving for enabling imple-
mentation in the daily clinical practice. In the pilot
study the expenditure of time was 15 minutes (me-
dian; interquartile range (IQR): 10–30). The feasibility
and acceptability was rated with a 5-point Likert scale in
different items (means: 3.2–4.2, SD 0.83–1.3). Other stud-
ies concerning improving appropriate prescription in
(mostly older) patients receiving complex polypharmacy
present a more time-consuming algorithm or method
than usual care [26]. The time aspect might be a strength
of our approach in comparison to other ongoing studies
[14, 15, 24].
A special feature of our study is the investigation of
overtreatment as well as undertreatment. After piloting
the study, an extension was made: beside the list of med-
ications in use a special section was added with “medica-
tion started.”
Prioritization of patient’s problems is a crucial issue in
the shared-decision-making process. To foster this ap-
proach and discussions between physician and patient
on this issue, we added a list of the four most important
complaints from the patient’s perspective to our tool in
in parallel with the list of the four major clinical prob-
lems defined by the PCP.
Based on other studies [24], measurements of EQ-5D-
3 L might even enable an economic evaluation of the
danger of adverse drug reactions.
Finally, our study contains an exploratory part, as
patient’s barriers and enablers against the approach will
be inquired systematically 13 months after intervention.
This has the potential to optimize the algorithm or fur-
ther adapt it to the specific needs of primary care.
Trial status
Patient recruitment had not started at the first submis-
sion in April 2015.
Abbreviations
GPGP: Good Palliative Geriatric Practice; HbA1c: glycated hemoglobin;
ICC: intracluster correlation coefficient; IQR: interquartile range; ITT: intent-to-
treat; LOCF: last observation carried forward; PCP: primary care physician;
PP: per-protocol; QoL: quality of life; SD: standard deviation; TSH: thyroid-
stimulating hormone.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
SN is the trial sponsor, he was the initiator for this study, organized the
recruitment and helped to draft the manuscript and to develop the case
report forms. OS conceived of the study, participated in the design of the
study and performed the statistical analysis. TR participated in the
coordination of the study. SH made the applications for ethical approval of
the study, developed the case report forms, organized the recruitment and
wrote and revised the final manuscript. All authors read and approved it.
Acknowledgments
This study is funded by Gottfried und Julia Bangerter-Rhyner-Stiftung, Basel
(Switzerland).
Hasler et al. Trials  (2015) 16:380 Page 6 of 7
Received: 27 April 2015 Accepted: 18 August 2015
References
1. Gallagher P, Lang PO, Cherubini A, Topinkova E, Cruz-Jentoft A, Montero
Errasquin B, et al. Prevalence of potentially inappropriate prescribing in an
acutely ill population of older patients admitted to six European hospitals.
Eur J Clin Pharmacol. 2011;67(11):1175–88. doi:10.1007/s00228-011-1061-0.
2. Wise J. Polypharmacy: a necessary evil. BMJ. 2013;347:f7033. doi:10.1136/
bmj.f7033.
3. Reeve E, To J, Hendrix I, Shakib S, Roberts MS, Wiese MD. Patient barriers
to and enablers of deprescribing: a systematic review. Drugs Aging.
2013;30(10):793–807. doi:10.1007/s40266-013-0106-8.
4. Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency
hospitalizations for adverse drug events in older Americans. N Engl J Med.
2011;365(21):2002–12. doi:10.1056/NEJMsa1103053.
5. Payne RA, Abel GA, Avery AJ, Mercer SW, Roland MO. Is polypharmacy
always hazardous? A retrospective cohort analysis using linked electronic
health records from primary and secondary care. Br J Clin Pharmacol.
2014;77(6):1073–82. doi:10.1111/bcp.12292.
6. Reich O, Rosemann T, Rapold R, Blozik E, Senn O. Potentially inappropriate
medication use in older patients in Swiss managed care plans: prevalence,
determinants and association with hospitalization. PLoS One. 2014;9(8),
e105425. doi:10.1371/journal.pone.0105425.
7. Hakkarainen KM, Hedna K, Petzold M, Hagg S. Percentage of patients with
preventable adverse drug reactions and preventability of adverse drug
reactions – -a meta-analysis. PLoS One. 2012;7(3), e33236. doi:10.1371/
journal.pone.0033236.
8. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in
hospitalized patients: a meta-analysis of prospective studies. JAMA.
1998;279(15):1200–5.
9. Kuijpers MA, van Marum RJ, Egberts AC, Jansen PA, Group OS. Relationship
between polypharmacy and underprescribing. Br J Clin Pharmacol.
2008;65(1):130–3. doi:10.1111/j.0306-5251.2007.02961.x.
10. Viktil KK, Blix HS, Moger TA, Reikvam A. Polypharmacy as commonly defined
is an indicator of limited value in the assessment of drug-related problems.
Br J Clin Pharmacol. 2007;63(2):187–95. doi:10.1111/j.1365-2125.2006.02744.x.
11. Gallagher PF, O’'Connor MN, O’Mahony D. Prevention of potentially
inappropriate prescribing for elderly patients: a randomized controlled trial
using STOPP/START criteria. Clin Pharmacol Ther. 2011;89(6):845–54.
doi:10.1038/clpt.2011.44.
12. Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH. Updating
the Beers criteria for potentially inappropriate medication use in older
adults: results of a US consensus panel of experts. Arch Intern Med.
2003;163(22):2716–24. doi:10.1001/archinte.163.22.2716.
13. Hanlon JT, Weinberger M, Samsa GP, Schmader KE, Uttech KM, Lewis IK, et
al. A randomized, controlled trial of a clinical pharmacist intervention to
improve inappropriate prescribing in elderly outpatients with polypharmacy.
Am J Med. 1996;100(4):428–37. doi:10.1016/S0002-9343(97)89519-8.
14. Jager C, Freund T, Steinhauser J, Joos S, Wensing M, Szecsenyi J. A
tailored implementation intervention to implement recommendations
addressing polypharmacy in multimorbid patients: study protocol
of a cluster randomized controlled trial. Trials. 2013;14:420.
doi:10.1186/1745-6215-14-420.
15. Altiner A, Schafer I, Mellert C, Loffler C, Mortsiefer A, Ernst A, et al. Activating
GENeral practitioners’ dialogue with patients on their Agenda (MultiCare
AGENDA) study protocol for a cluster randomized controlled trial. BMC Fam
Pract. 2012;13:118. doi:10.1186/1471-2296-13-118.
16. Schuling J, Gebben H, Veehof LJ, Haaijer-Ruskamp FM. Deprescribing
medication in very elderly patients with multimorbidity: the view
of Dutch GPs. A qualitative study. BMC Fam Pract. 2012;13:56.
doi:10.1186/1471-2296-13-56.
17. Matthys J, Elwyn G, Van Nuland M, Van Maele G, De Sutter A, De Meyere M,
et al. Patients’ ideas, concerns, and expectations (ICE) in general practice:
impact on prescribing. British J Gen Pract. 2009;59(558):29–36.
doi:10.3399/bjgp09X394833.
18. Mahler C, Hermann K, Jank S, Haefeli WE, Szecsenyi J. Can a feedback report
and training session on medication counseling for general practitioners
improve patient satisfaction with information on medicines? Patient
Preference Adherence. 2012;6:179–86. doi:10.2147/PPA.S27378.
19. Garfinkel D, Zur-Gil S, Ben-Israel J. The war against polypharmacy: a new
cost-effective geriatric-palliative approach for improving drug therapy in
disabled elderly people. IMAJ. 2007;9(6):430–4.
20. Garfinkel D, Mangin D. Feasibility study of a systematic approach for
discontinuation of multiple medications in older adults: addressing
polypharmacy. Arch Intern Med. 2010;170(18):1648–54. doi:10.1001/
archinternmed.2010.355.
21. Neuner-Jehle S, Krones T, Senn O. Systematic elimination of prescribed
medicines is acceptable and feasible among polymorbid family medicine
patients. Praxis. 2014;103(6):317–22. doi:10.1024/1661-8157/a001591.
22. EuroQol G. EuroQol – a new facility for the measurement of health-related
quality of life. Health Policy. 1990;16(3):199–208.
23. Brooks R. EuroQol: the current state of play. Health Policy. 1996;37(1):53–72.
24. Willeboordse F, Hugtenburg JG, van Dijk L, Bosmans JE, de Vries OJ,
Schellevis FG, et al. Opti-Med: the effectiveness of optimised clinical
medication reviews in older people with ‘geriatric giants’ in general
practice; study protocol of a cluster randomised controlled trial. BMC
Geriatr. 2014;14:116. doi:10.1186/1471-2318-14-116.
25. Greiner W, Claes C, Busschbach JJ, von der Schulenburg JM. Validating the
EQ-5D with time trade off for the German population. European J Health
Econ. 2005;6(2):124–30.
26. Drenth-van Maanen AC, van Marum RJ, Knol W, van der Linden CM, Jansen
PA. Prescribing optimization method for improving prescribing in elderly
patients receiving polypharmacy: results of application to case histories by
general practitioners. Drugs Aging. 2009;26(8):687–701. doi:10.2165/
11316400-000000000-00000.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Hasler et al. Trials  (2015) 16:380 Page 7 of 7
